Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Life science management for hire

Do you need help getting your biotech company off and running? Camoleon is a new type of consultant that offers help with business and innovation management and...

Test if you carry the fat virus

In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.

Ambassador program makes MVA big in Japan

The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a signifi...

Focusing on Medicon Valley

Copenhagen Capacity and Invest in Skåne are hosting a seminar to promote the geographical area known as Medicon Valley. Some of the 350 life science companies f...

Medicult acquires embryo scanner

The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...

Vitrolife wants to acquire Medicult

The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.

Re-painting the big pig-ture

Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.

Norwegian cancer therapy leaves phase II

New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.

Orion cuts 205 jobs

The Finnish company Orion has completed its statutory negotiations. By this, personnel will be reduced by about 205 in Finland.

SP vill göra Astra Zenecas säkerhetsenhet till institut

Statens tekniska forskningsinstitut har på uppdrag av Vinnova tagit Ernst and Youngs rapport vidare. Nu vill de göra Astra Zenecas säkerhetsenhet till ett nytt SP-institut.

”Alla skriker efter talang”

Att locka till sig begåvningarna är en av life science-branschens stora framtidsutmaningar. Det var en av slutsatserna i det panelsamtal som avslutade konferensen New Horizons in Biologics & Bioprocessing på torsdagen....

Life Science Sweden Executive

Your partnering tool - step by step

Profile, agenda and requests. Those are the basic steps to follow to use the partnering tool for Biotech Forum. Follow our guide to successful partnering!

LEO Pharma - International Clinical Trial Manager

Multilabel plate readers with luminescence capability

The Enspire Multilabel Plate Reader platform from Perkin Elmer now features sensitive luminescence detection. The new detection capability is primarily aimed at...

New tools to fight bacteria

Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...

Rapportvågen är här

Blandade prestationer för sex av life science-bolagen under årets första kvartal.

Små gottegrisar förklaras biologiskt

Barns sug efter socker är medfött och avtar i takt med att vi slutar växa visar en ny studie.

Generaldirektörernas saftiga löneökning

Medan vanliga löntagares lön ökat med 13 procent de senaste fem åren har myndighetschefernas lön ökat med 18 procent, visar en kartläggning som Dagens Nyheter gjort.

New map of eye proteins

A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.